Neuberger Berman Group LLC Has $1.10 Million Stake in Insmed, Inc. $INSM

Neuberger Berman Group LLC lowered its position in shares of Insmed, Inc. (NASDAQ:INSM) by 93.8% during the second quarter, HoldingsChannel.com reports. The fund owned 10,895 shares of the biopharmaceutical company’s stock after selling 165,738 shares during the quarter. Neuberger Berman Group LLC’s holdings in Insmed were worth $1,096,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. ORG Partners LLC lifted its stake in shares of Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank acquired a new stake in Insmed during the second quarter worth approximately $28,000. FNY Investment Advisers LLC bought a new stake in Insmed in the second quarter worth approximately $33,000. LRI Investments LLC bought a new stake in Insmed in the second quarter worth approximately $59,000. Finally, EverSource Wealth Advisors LLC lifted its stake in Insmed by 65.6% in the second quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 263 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on INSM. Jefferies Financial Group set a $269.00 price objective on shares of Insmed in a research report on Wednesday. The Goldman Sachs Group increased their target price on shares of Insmed from $196.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Cowen restated a “buy” rating on shares of Insmed in a report on Wednesday. UBS Group lifted their price target on shares of Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Mizuho increased their price objective on shares of Insmed from $196.00 to $256.00 and gave the stock an “outperform” rating in a research report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $196.26.

Insider Buying and Selling at Insmed

In other Insmed news, Director Leo Lee sold 75,000 shares of Insmed stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the completion of the transaction, the director owned 54,677 shares in the company, valued at approximately $10,711,224.30. The trade was a 57.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total value of $5,820,000.00. Following the sale, the insider directly owned 36,461 shares of the company’s stock, valued at $7,073,434. This represents a 45.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 147,130 shares of company stock worth $28,480,051 in the last quarter. 3.00% of the stock is owned by insiders.

Insmed Stock Performance

Shares of INSM stock opened at $197.01 on Monday. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The firm has a fifty day simple moving average of $185.10 and a two-hundred day simple moving average of $139.92. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75. The firm has a market capitalization of $42.02 billion, a PE ratio of -31.83 and a beta of 1.01.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm’s quarterly revenue was up 52.4% on a year-over-year basis. During the same period last year, the business posted ($1.27) earnings per share. Analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.